Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ: ELDN )

3.690 +0.090 (+2.50%)
Streaming Delayed Price Updated: 11:43 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eledon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Recap: Eledon Pharma Q1 Earnings
Via Benzinga
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharma's Earnings: A Preview
Via Benzinga
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Management to host conference call and webcast at 4:30 p.m. ET 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals's Earnings: A Preview
Via Benzinga
Eledon Pharma: Q2 Earnings Insights
  Eledon Pharma (NASDAQ:ELDN) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
Management to host conference call and webcast at 4:30 p.m. ET 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
Additional poster presentation to detail high-dose cohort safety data from Phase 2a trial of tegoprubart in IgA Nephropathy (IgAN) 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Provides Business and Pipeline Updates
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
From eGenesis
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Management to host conference call and webcast at 4:30 pm ET 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average... 
Via Benzinga
Eledon Shares Climb After Securing FDA Nod For Mid-Stage Kidney Disease Study
Eledon Pharmaceuticals (NASDAQ: ELDN) received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Eledon Pharmaceuticals Earnings: A Preview
  Eledon Pharmaceuticals (NASDAQ:ELDN) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Eledon Secures FDA Clearance For Kidney Transplant Rejection Study
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ: ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.